By Colin Kellaher 
 

Abbott Laboratories (ABT) in Monday said the U.S. Food and Drug Administration approved the Amplatzer Piccolo Occluder for the treatment of a common congenital heart defect in premature babies and newborns.

The Abbott Park, Ill., maker of health-care products said the Amplatzer Piccolo is the first and only minimally invasive, transcatheter treatment specifically approved for premature babies with patent ductus arteriosus, a life-threatening opening in the heart.

Abbott said the occluder, which can be implanted in babies weighing as little as two pounds, is a self-expanding, wire mesh device tinier than a small pea that is used to seal the opening in the heart.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

January 14, 2019 09:36 ET (14:36 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Abbott Laboratories Charts.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Abbott Laboratories Charts.